Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (37,509)	$ (53,373)	$ (75,067)	$ (49,329)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense			79	25
Amortization of debt discount			0	191
Change in fair value of contingent consideration liability - related parties	(95)	911	(95)	660
Change in fair value of securities carried at fair value	584	0	1,324	0
Change in fair value of derivative liability	0	0	0	(41)
Change in Fair Value Of Warrant Liability			(53)	40
Unrealized loss on other investments held at fair value	0	5,460	0	5,460
Gain on dilution of equity method investment	0	(16,923)	0	(16,923)
Loss on conversion of convertible notes			0	513
Gain on consolidation of a variable interest entity	0	(3,543)	0	(3,543)
Losses from investments in equity method investees			12,242	4,641
In-process research and development expense			357	8,934
Stock-based compensation expense			19,720	37,724
Unrealized foreign exchange gains			(4,966)	0
Other			(134)	41
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			939	(1,674)
Accounts payable			(2,591)	2,380
Accrued liabilities			2,328	(3,846)
Deferred revenue			0	120
Net cash used in operating activities			(45,917)	(14,627)
Cash flows from investing activities
Purchases of property and equipment			(172)	(298)
Capitalized internal-use software development costs			(100)	(155)
Cash paid for securities carried at fair value			(229,678)	0
Cash acquired in asset acquisitions, net			0	47
Cash paid for equity method investments			0	(5,359)
Cash paid for other investments			0	(23,445)
Loans to related parties			(3,000)	(2,624)
Cash paid for other assets			0	(195)
Net cash used in investing activities			(232,950)	(32,029)
Cash flows from financing activities
Proceeds from issuance of common stock			0	409,884
Cash paid for deferred offering costs			0	(10,161)
Proceeds from issuance of share option awards			0	534
Proceeds from sale of investment			0	2,417
Proceeds from issuance of shares upon exercise of stock options			249	0
Proceeds from issuance of subsidiary preferred shares			600	0
Proceeds from conversion of convertible notes to common stock			1,077	0
Proceeds from issuance of convertible promissory notes			0	1,588
Net cash provided by financing activities			1,926	404,262
Effect of foreign exchange rate changes on cash			(1,193)	(1,230)
Net increase (decrease) in cash and cash equivalents			(278,134)	356,376
Cash and cash equivalents – beginning of the period			362,266	97,246	$ 97,246
Cash and cash equivalents – end of the period	$ 84,132	$ 453,622	84,132	453,622	$ 362,266
Supplemental disclosures of non cash investing and financing information:
Right of use asset obtained in exchange for operating lease liabilities			487	0
Issuance of subsidiary shares to non-controlling interests in connection with Columbia stock purchase agreement			357	0
Common stock issuance costs in accounts payable			0	230
Common stock issuance costs in accrued liabilities			0	1,958
Fair value of noncontrolling interests issued in connection with consolidation of a VIE			0	392
Fair value redeemable noncontrolling interests issued in connection with consolidation of a VIE			0	2,555
Fair value of noncontrolling interests issued in connection with asset acquisitions			0	885
Issuance of derivative instrument related to convertible promissory notes			0	646
Issuance of subsidiary shares in connection with the conversion of convertible notes			$ 0	$ 3,257